Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

MD-7246

Other · developed by Ironwood Pharmaceuticals

Phase 2 Most advanced trial (none active)
IRWD Developer
1 Registered trials

What is MD-7246?

MD-7246 is an investigational drug studied in Irritable Bowel Syndrome With Diarrhea (IBS-D).

At a glance

Drug type
Other
Therapy area
Gastroenterology
Developer
Ironwood Pharmaceuticals, Inc. (IRWD)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT03931785 Phase 2 Irritable Bowel Syndrome With Diarrhea (IBS-D) Completed IRWD

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Irritable Bowel Syndrome With Diarrhea (IBS-D)

More from Ironwood Pharmaceuticals

Lesinurad FDA approved IW-3300 Phase 2 IW-6118 Phase 2 IW-9179 Phase 2 MD-0727 Phase 2

Follow IRWD, the company behind MD-7246

See IRWD's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

IRWD catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.